TXNIP (VDUP-1, TBP-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms
TXNIP (VDUP-1, TBP-2): A major redox regulator commonly suppressed in cancer by epigenetic mechanisms
复制标题
DOI：
10.1016/j.biocel.2011.09.005
复制
发表时间：
2011-12-01
影响因子：
4
通讯作者：
Chng, Wee-Joo
中科院分区：
文献类型：
--
作者：
Zhou, Jianbiao;Yu, Qiang;Chng, Wee-Joo
TXNIP（也称为VDUP-1或TBP-2）最初在用维生素D3处理的HL 60细胞中分离。随后，它已被确定为各种实体瘤和血液恶性肿瘤中的主要氧化还原调节剂和肿瘤抑制基因（TSG）。在本综述中，我们将首先提供TXNIP基因和蛋白质结构的概述，随后总结的研究，已证明其在人类癌症和相关的临床意义，以及在动物模型中的功能表征的频繁镇压。然后，我们将强调我们目前对TXNIP信号传导和生物学功能的了解。接下来，我们将讨论清楚地表明TXNIP在癌症中通过各种分子机制的表观遗传沉默的证据。小分子抑制剂的治疗用途，重新激活TXNIP表达的癌症治疗也将在此审查进行讨论。(C)2011爱思唯尔有限公司保留所有权利。
TXNIP (also named as VDUP-1 or TBP-2) was originally isolated in HL60 cells treated with Vitamin D3. Subsequently, it has been identified as a major redox regulator and a Tumor Suppressor Gene (TSG) in various solid tumors and hematological malignancies. In the present review, we will first provide an overview of TXNIP gene and protein structures, followed by a summary of the studies that have demonstrated its frequent repression in human cancers and relevant clinical significance, as well as functional characterization in animal models. We will then highlight our current knowledge of TXNIP signaling and biological functions. Next, we will discuss the evidence that clearly have demonstrated that the epigenetic silencing of TXNIP in cancer through various molecular mechanisms. The therapeutic use of small molecular inhibitors to reactivate TXNIP expression for cancer treatment will also be discussed in this review. (C) 2011 Elsevier Ltd. All rights reserved.